Ectopic bone formation in cell-seeded poly(ethylene oxide)/poly(butylene terephthalate) copolymer scaffolds of varying porosity by Claase, Menno B. et al.
Ectopic bone formation in cell-seeded poly(ethylene oxide)/
poly(butylene terephthalate) copolymer scaffolds of varying
porosity
Menno B. Claase Æ Joost D. de Bruijn Æ
Dirk W. Grijpma Æ Jan Feijen
Received: 23 December 2005/Accepted: 5 July 2006/Published online: 1 February 2007
  Springer Science+Business Media, LLC 2007
Abstract Scaffolds from poly(ethylene oxide) and
poly(butylene terephthalate), PEOT/PBT, with a PEO
molecular weight of 1,000 and a PEOT content of 70
weight% (1000PEOT70PBT30) were prepared by
leaching salt particles (425–500 lm). Scaffolds of 73.5,
80.6 and 85.0% porosity were treated with a CO2 gas
plasma and seeded with rat bone marrow stromal cells
(BMSCs). After in vitro culture for 7 days (d) in an
osteogenic medium the scaffolds were subcutaneously
implanted for 4 weeks in nude mice. Poly(D, L-lactide)
(PDLLA) and biphasic calcium phosphate (BCP)
scaffolds were included as references.
After 4 weeks (wks) all scaffolds showed ectopic
formation of bone and bone marrow. For the scaffolds
of different porosities, no signiﬁcant differences were
observed in the relative amounts of bone (7–9%) and
bone marrow (6–11%) formed, even though micro
computed tomography (l-CT) data showed consider-
able differences in accessible pore volume and surface
area. 1000PEOT70PBT30 scaffolds with a porosity of
85% could not maintain their original shape in vivo.
Surprisingly, 1000PEOT70PBT30 scaffolds with a
porosity of 73.5% showed cartilage formation. This
cartilage formation is most likely due to poorly
accessible pores in the scaffolds, as was observed in
histological sections. l-CT data showed a considerably
smaller accessible pore volume (as a fraction of the
total volume) than in 1000PEOT70PBT30 scaffolds of
80.6 and 85.0% porosity. BMSC seeded PDLLA
(83.5% porosity) and BCP scaffolds (29% porosity)
always showed considerably more bone and bone
marrow formation (bone marrow formation is approx-
imately 40%) and less ﬁbrous tissue ingrowth than the
1000PEOT70PBT30 scaffolds.
The scaffold material itself can be of great inﬂuence.
In more hydrophobic and rigid scaffolds like the
PDLLA or BCP scaffolds, the accessibility of the pore
structure is more likely to be preserved under the
prevailing physiological conditions than in the case of
hydrophilic 1000PEOT70PBT30 scaffolds. Scaffolds
prepared from other PEOT/PBT polymer composi-
tions, might prove to be more suited.
1 Introduction
Large bone defects do not heal spontaneously and
require surgical intervention for restoration. The
inherent drawback of the use of autologous trabecular
grafts, however, is that the grafts have to be removed
from another place in the human body, resulting in
donor-site morbidity [1]. A possible alternative is the
use of allogeneic bone. This, however, shows a lower
osteogenic capacity, a higher resorption rate, a larger
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123immunogenic response and less extensive revasculari-
zation of the graft. Furthermore there are concerns
over the possibility of viral contamination of the graft
material and possible transmission of live virus to the
recipient. The rapidly developing ﬁeld of tissue engi-
neering offers advantageous approaches for defect
repair.
As scaffold materials, porous polymers have
attracted much attention [2]. Due to the vast variety
of preparation techniques, many different polymeric
scaffold architectures can be obtained. The mechanical
and physical properties of poly(ethylene oxide)/
poly(butylene terephthalate) (PEOT/PBT) segmented
block copolymers can be tuned by varying the PBT
(hard segment) content and PEO (soft segment)
content and molecular weight [3, 4]. These properties
make these copolymers interesting candidates for use
as scaffold materials in (bone) tissue engineering.
Besides this, several subcutaneous and intra-bone
(tibia) implantations of dense and porous blocks and
porous ﬁlms in rats and goats showed bonding to bone,
calciﬁcation and degradation for PEOT/PBT copoly-
mers with high PEO content (1000PEOT60PBT40 and
1000PEOT70PBT30, prepared from polyethylene gly-
col of molecular weight 1000 g/mol with respectively 60
and 70 wt% PEOT hydrophilic soft segments and 40
and 30 wt% hydrophobic PBT hard segments) [5–9].
However, after implantation of porous blocks of
1000PEOT70PBT30 in goat [10] and human [11] ilia
critical size defects, poor bone bonding, limited calci-
ﬁcation and limited fragmentation were, observed. It is
anticipated that seeding 1000PEOT70PBT30 scaffolds
with BMSCs will yield structures with osteoinductive
properties [12] that are better suited for bone tissue
engineering than the scaffolds without BMSCs.
The in vitro culture of (rat) bone marrow stromal
cells (BMSCs) in an osteogenic medium containing
dexamethasone, b-glycerophosphate and L-ascorbic
acid greatly increases the amount of cells with an
osteoblastic phenotype [13–16]. In many systems,
seeding of BMSCs (after expansion in culture) on a
porous scaffold, followed by a period of in vitro cell
culture in an osteogenic medium prior to implantation,
resulted in enhanced ectopic bone formation compared
to scaffolds that were seeded and implanted immedi-
ately [17, 18].
Besides the culturing conditions, it was shown for
PLGA scaffolds that scaffold morphology (i.e., pore
size and porosity) can also inﬂuence the in vivo results
[18]. Until now, the porosity of 1000PEOT70PBT30
scaffold materials has not been optimized for bone
tissue engineering. To study the effect of porosity and
accessible pore volume on ectopic bone formation,
CO2 plasma treated 1000PEOT70PBT30 scaffolds of
73.5, 80.6 and 85.0 % porosity were prepared by
leaching salt particles of 425–500 lm and subcutane-
ously implanted in nude mice after seeding with rat
BMSCs and in vitro culture for 7 d (days) in an
osteogenic medium. Ectopic bone formation was
evaluated and quantiﬁed by histomorphometry.
2 Materials and methods
2.1 Materials
The 1000PEOT70PBT30 copolymer was prepared as
previously described [19], PDLLA, inherent viscosity
2.96 dl/g, was obtained from Purac (Gorinchem, The
Netherlands), and puriﬁed by precipitation. Porous
structures were prepared by compression molding of
polymer/salt mixtures followed by salt leaching. The
salt particle size used was 425–500 lm. Scaffolds of
4m m· 4m m· 4 mm were cut with a razor blade and
treated with a CO2 plasma [20]. Porosities were
determined by measurement of scaffold mass and
dimensions, using a density of q = 1.188 g/cm
3 for solid
1000PEOT70PBT30 and q = 1.26 g/cm
3 for PDLLA.
Bicalcium phosphate granules [17] (OsSatura
TM, BCP)
were characterized by mercury intrusion porosimetry
and provided by Isotis OrthoBiologics (Bilthoven, The
Netherlands).
2.2 Cell culturing and implantation
Bone marrow stromal cells were isolated from 16
femora of 8 young male Wistar-rats (100–120 g). The
osteogenic culture medium was minimal essential
medium (a-MEM, Life Technologies, The Nether-
lands) containing [13]: 15% fetal bovine serum,
100 units/ml penicillin, 100 lg/ml streptomycin, 2 mM
L-glutamine, 0.2 mM ascorbic acid 2-phosphate,
10 mM b-glycerophosphate, 10
–8 M dexamethasone.
The scaffolds were put in culture medium overnight
and seeded with 2 · 150 ll of cell suspension (approx-
imately 2 · 10
5 cells per scaffold). Cell suspensions
were injected into the scaffolds with a pipette tip.
Scaffolds were incubated at 37 C for 3 hours (h), after
which 2 ml of cell culture medium was added. Cells
were cultured at 37 C, 5 % CO2 for 7 d, with periodic
medium changes every other day. At day 7 the samples
were either implanted or analyzed using SEM or a
DNA assay.
Cell-seeded and cultured scaffolds were subcutane-
ously implanted in six immunodeﬁcient mice (six sites
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sacriﬁced and the scaffolds were removed and ﬁxed
with glutaraldehyde (1.5% solution in cacodylic acid
buffer). One mouse died prematurely and the
implanted scaffolds were excluded from the experi-
ment. For each of the 1000PEOT70PBT30 scaffolds 5
samples were analyzed, unless otherwise mentioned.
2.3 Analyses
Compression moduli of scaffolds (height 8 mm, diam-
eter 17 mm) were determined at 10% strain in tripli-
cate at room temperature using a Zwick Z020 tensile
tester operating at 2 mm/min.
Dry, unseeded scaffolds were scanned using a
Micro-CT from Scanco Medical (Bassersdorf, Switzer-
land). The porosity is calculated from the number of
polymer voxels and the total number of voxels. To
determine the pore size, the diameter of a largest
modeled sphere ﬁtting in the (cubic) pore is assigned to
all voxels within that pore.
An algorithm mimicking mercury intrusion porosi-
metry was used to determine the accessible pore
volume, and its surface area was calculated using a
triangularization algorithm. In a following paper the
micro-CT analysis will be dealt with in more detail.
Scaffolds containing rat BMSCs were ﬁxed, dehy-
drated and dried, then coated with Au/Pd and
observed with a Hitachi FE-SEM S-800 scanning
electron microscope (SEM).
To determine the DNA (and cell) content, scaffolds
were washed with phosphate buffered saline (PBS) and
incubated at 56 C overnight in 0.5 ml of proteinase K
lysis-medium (Sigma, The Netherlands) to lyse all cells.
Then250 llofthesesuspensionsweremixedwith250 ll
RNase-solution. (prepared from 30 ll RNase (Sigma,
The Netherlands, 1.35 Kunitz units/ll) and 50 ll hepa-
rin (Leopharma, The Netherlands, 5,000 IE/ml) in
12.5 ml PBS, and incubated at 37 C for 60 min to
remove single stranded RNA and DNA. Various dilu-
tions were prepared with PBS and mixed with
CyQUANT
  dye. After 15 min, the ﬂuorescence of
the solutions in 96 well plates was measured. The
intensities were correlated to the amount of DNA using
a calibration curve of DNA (Sigma) dilutions of known
concentration. Data shown are the result of triplicate
measurements ± SD).
Scaffolds were dehydrated and subsequently embed-
ded in poly(methyl methacrylate) (PMMA), then
sections were prepared and stained using 1% methy-
lene blue and 0.3% basic fuchsine solutions. Samples
were evaluated histologically and histomorphometri-
cally by light microscopy. Sections from the middle
part of the scaffolds were analyzed at high magniﬁca-
tions and the relative amounts of the different tissues
formed ectopically were calculated from the number of
pixels using Scion Image software. Data shown are the
average of 5 scaffolds ± SD, unless otherwise
mentioned.
3 Results and discussion
Six different scaffolds, seeded with rat BMSCs and
cultured for 7 d in an osteogenic medium, were
subcutaneously implanted in immunodeﬁcient nude
mice and evaluated for tissue formation. The used
scaffolds are depicted in Fig. 1 and some of their main
characteristics are summarized in Table 1.
Three 1000PEOT70PBT30 scaffolds differing in
porosity (scaffolds A, B and C) were treated using a
CO2plasma.Untreated1000PEOT70PBT30(scaffoldF)
seeded with rat BMSCs and cultured for 7 d in an
osteogenicmedium,wereusedasanegativecontrolforin
vivo bone formation. For comparison scaffolds were also
prepared from PDLLA (scaffold D), a well-known
biomaterial. Cell-seeded and cultured biphasic calcium
phosphate (OsSatura
TM BCP, scaffold E) was used as a
positivecontrolforinvivoboneformationtoconﬁrmthe
osteogenic potential of the cells used [22].
The actual porosity of the prepared scaffolds is
higher than expected from the used salt volume, and
the compression modulus decreases signiﬁcantly with
increasing porosity. The scaffolds (dry, prior to gas
plasma treatment and cell seeding) were characterized
using micro computed tomography (l-CT). Relevant
parameters like scaffold porosity and pore size distri-
bution were also calculated. As shown in Table 1, the
porosity obtained from l-CT matches the values
determined by density measurements quite well. Pore
size distributions are given in Fig. 2A. The pore size
distributions of the 1000PEOT70PBT30 scaffolds A, B
and C with pore sizes up to 648 lm are comparable, as
was expected for scaffolds prepared with salt of the
same particle size. The pore size distributions of
PDLLA (D) (pore sizes up to 760 lm) and BCP (E)
(pore sizes up to 1000 lm) are noticeably different
from the 1000PEOT70PBT30 scaffolds. The average
pore sizes of the 1000PEOT70PBT30 scaffolds (318,
342 and 311 lm for the scaffolds A, B, and C
respectively) and the PDLLA scaffold (407 lm) are
smaller than the size of the salt particles used
(425–500 lm).
The accessible pore volume of the scaffolds was
determined using l-CT data. The resulting graphs of
the accessible pore volume (given as a fraction of the
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the algorithm are shown in Fig. 2B. Even though the
average pore sizes and pore size distributions are
comparable, there are considerable differences in
accessible pore volume of the 1000PEOT70PBT30
scaffolds.
The curve for scaffold A shows that there is much
less accessible pore volume at sphere diameters below
300 lm than for the 1000PEOT70PBT30 scaffolds B
and C and PDLLA scaffold D. The accessible pore
volume of the 1000PEOT70PBT30 scaffolds B and C is
quite comparable, showing that the increase in scaffold
porosity of 80.6–85.0% does not result in a larger
accessible pore volume. For all sphere diameters the
accessible pore volume of PDLLA scaffold D is higher
than (or equal to) the accessible pore volume of the
1000PEOT70PBT30 scaffolds.
With increasing porosity one would expect a larger
surface area available for the BMSCs to attach to and
proliferate on, although this area can depend on pore
geometry, pore size and size distribution and on pore
interconnectivity. For simulated sphere diameters up to
Fig. 1 3D generated
computer images constructed
from l-CT scans of dry
scaffolds, prior to gas plasma
treatment and cell seeding.
The images corresponding to
scaffolds A, B, C, D, E and F
(identical to A) as listed in
Table 1 are shown
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ity indeed has a higher accessible surface area than
scaffold B of 80.6% porosity (Fig. 2C). Surprisingly
scaffold A with the lowest porosity of 73.5% shows the
highest accessible surface area (for simulated spheres
with a diameter (d) up to 100 lm) and PDLLA scaffold
D of 83.5% porosity shows the lowest accessible surface
area of the polymeric scaffolds. Here pore size is
important too, as for comparable porosities, a smaller
pore size will result in a larger available surface area.
Rat BMSCs were seeded on the scaffolds (static
seeding, 2 · 10
5 cells/scaffold) and cultured for 7 d in
an osteogenic medium. To estimate the number of cells
present on and in the different cell-seeded and cultured
scaffolds, the DNA was ﬂuorimetrically quantiﬁed
using CyQuant
  dye. The results are presented in
Fig. 3.
The higher amounts of DNA present in scaffold C
(85.0% porosity), as compared to scaffold B (80.6%
porosity), reﬂect the increase in surface area available
for the cells with increasing porosity. Scaffold A shows
the smallest amount of DNA even though l-CT data
indicates that this scaffold has the largest accessible
surface area (for sphere diameters smaller than
100 lm). After 7 d of culture both the PDLLA and
BCP scaffolds (D and E) contain a signiﬁcantly lower
amount of DNA (and hence cells) than the gas plasma
treated 1000PEOT70PBT30 A, B and C scaffolds. This
is likely due to a limited accessible surface area.
Following the subcutaneous implantation in nude
mice to induce ectopic bone formation, the scaffolds
were explanted, microtomed and stained using meth-
ylene blue and basic fuchsin. This allows differentiating
between formed bone, bone marrow, cartilage and
ﬁbrous tissues [23]. The amounts of the different
tissues formed were determined in middle cross
sections of the different scaffolds (implanted in 5-fold)
and averaged. The porosity (area corresponding to
pores) and the amounts (relative areas) of the different
formed tissues (normalized for the porosity) are shown
in Table 2. Cross-sections taken from the middle of the
scaffolds are shown in Fig. 4.
When comparing scaffold A, B and C not much
difference is observed in terms of the amount of bone
and bone marrow tissue formed (see Table 2). Several
scaffold C implants were severely distorted upon
explantation (data not shown) and it seems that their
rigidity is not adequate for use under these conditions.
Scaffold E (BCP) clearly shows the ability of the used
BMSCs to induce ectopic bone formation upon implan-
tation, as bone and bone marrow are abundantly
present on the surface of the scaffold. The negative
control scaffold F (untreated 1000PEOT70PBT30,
seeded with rat BMSCs and cultured for 7 d in an
osteogenic medium) does not show any formation of
bone or bone marrow.
The relative amounts of ectopic bone formed in the
four different cell-seeded polymeric scaffolds are
comparable and vary from 7 to 9%. All
1000PEOT70PBT30, PDLLA and BCP scaffolds show
bone marrow formation. The PDLLA scaffold con-
tained considerably more bone marrow than the
1000PEOT70PBT30 scaffolds, even though at the time
of implantation there was signiﬁcantly less DNA (and
hence cells) present in the PDLLA scaffold. Besides
bone and bone marrow, fairly high amounts of ﬁbrous
tissue were observed in many of the scaffolds. In line
with previous work [17, 23], the observation of ectopic
Table 1 Main characteristics of scaffolds used in cell seeding and implantation. The dry, unseeded scaffolds were scanned before gas
plasma treatment
Scaffold description Salt fraction
used (lm)
Salt volume
used (%)
Average pore
size from l-CT (lm)
Porosity
a from
l-CT (%)
Compression modulus
(dry) (N/mm
2)
A: 1000PEOT70PBT30 Gas
plasma treated
b
425–500 60 318 69.8 (73.5 ± 0.5) 0.33 ± 0.02
B: 1000PEOT70PBT30 Gas
plasma treated
425–500 70 342 78.2 (80.6 ± 0.6) 0.14 ± 0.03
C: 1000PEOT70PBT30 Gas
plasma treated
425–500 80 311 81.6 (85.0 ± 0.6) 0.03 ± 0.01
D: PDLLA Not treated 425–500 80 407 81.7 (83.5 ± 0.7) 2
c
E: OsSatura
TM BCP Not
treated
382
d – 837 36.2 (29
e) n.d.
a Porosity as obtained from density measurements is shown in parentheses
b Scaffold F = A without gas plasma treatment
c Approximate value based on reference [21]
d Average pore size, as determined by mercury intrusion porosimetry, pores < 100 lm were excluded
e Average porosity, as determined by mercury intrusion porosimetry, pores < 100 lm were excluded
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and BCP porous structures again shows their potential
as scaffold materials for the tissue engineering of bone.
Surprisingly, scaffold A (porosity 73.5%) also
showed cartilage formation besides bone and bone
marrow. The scaffold stiffness can greatly affect
cartilage formation in vivo [24, 25]. Although the
effect of scaffold stiffness on cartilage formation
cannot be excluded, there is another more likely
explanation for the observation of cartilage formation.
From the histological sections it appears that the pores
in which cartilage formation takes place are not well
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Fig. 2 (A) Pore size
distributions and average
pore sizes derived from l-CT.
Scaffolds A, B, C and D were
prepared using salt crystals of
425–500 lm. Scaffold F is
identical to scaffold A; (B)
Accessible pore volume (as a
fraction of the total volume)
versus sphere diameter (d) for
unseeded and dry scaffolds
A–E. Notice the lower
accessible pore volume of
scaffold A; (C) Accessible
surface area (normalized for
the total volume) versus
sphere diameter (d) for
unseeded and dry scaffolds
A–E
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favored by conditions in which the oxygen supply is
limited [26]. Implantation of demineralized teeth
resulted in cartilage formation when one side was left
open and in bone formation when both sides where left
open. A comparable observation was made after
implantation of hydroxyapatite with channel-like
pores, where cartilage was observed in the central
zones of the pores [27]. Vascularization is needed for
adequate oxygen and nutrient supply and is therefore
believed to be of great importance for bone formation
[28]. Vascularization of tissue within a scaffold with
large pores but with small pore interconnections may
be difﬁcult [29].
The poor accessibility of this pore structure also
follows from l-CT. Rat BMSC seeding on the
1000PEOT70PBT30 scaffold A also shows consider-
ably less ingrowth of ﬁbrous tissue and contains much
more wound exudate upon implantation than when
using the other scaffolds.
4 Conclusions
After culturing in an osteogenic medium, the BMSC
seeded polymer scaffolds described are suited for bone
tissue engineering. All implanted cell-seeded scaffolds
show bone and bone marrow formation. By varying the
scaffold porosity of 1000PEOT70PBT30 scaffolds it
was possible to obtain scaffolds with comparable pore
size distributions, but with considerable differences in
accessible pore volume. However, no signiﬁcant dif-
ferences between the different 1000PEOT70PBT30
scaffolds were observed in terms of ectopically formed
bone (7–9%) and bone marrow (6–11%). Surprisingly,
1000PEOT70PBT30 scaffolds with a porosity of 73.5%
showed cartilage formation. Although the effect of
scaffold stiffness cannot be excluded, cartilage forma-
tion is most likely due to a poorly accessible pore
network.
BMSC seeded PDLLA and BCP scaffolds showed
considerably more bone and bone marrow formation and
less ﬁbrous tissue in-growth than the 1000PEOT70PBT30
scaffolds, although both scaffolds contained much less
cells (as determined by a DNA assay) upon implantation.
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Fig. 3 Fluorimetric quantiﬁcation of DNA in the scaffolds after
7 d of culture in an osteogenic medium of rat BMSC culture
(triplicate measurements). *: Value signiﬁcantly different from
the other 5 scaffolds. A: 1000PEOT70PBT30, 73.5% porous,
average pore size 318 lm; B: 1000PEOT70PBT30, 80.6%
porous, 342 lm; C: 1000PEOT70PBT30, 85.0% porous,
311 lm; D: PDLLA, 83.5% porous, 407 lm; E: BCP, 29%
porous, average pore size: 837 lm; F: 1000PEOT70PBT30,
73.5% porous, untreated
Table 2 Amounts (%) of bone, bone marrow, cartilage, ﬁbrous tissue and wound exudate. The porosity is the relative area of the cross
section corresponding to pores. The results are the average of 5 scaffolds (±s.d.), unless mentioned otherwise. Middle cross-sections of
the explanted scaffolds were analyzed
Porosity
a
(%)
Bone (%) Bone marrow
(%)
Cartilage
(%)
Fibrous tissue
(%)
Wound exudate
(%)
A 1000PEOT70PBT30 73.5 % porous 52.9 ± 10.3 7.2 ± 2.6 7.6 ± 4.5 4.7 ± 2.9 22.8 ± 6.8 35.5 ± 12.2
b
B 1000PEOT70PBT30 80.6 % porous 65.8 ± 8.0 8.6 ± 5.0 6.4 ± 5.5 0.1 ± 0.2
c 58.0 ± 4.8 8.9 ± 5.9
C 1000PEOT70PBT30 85.0 % porous 68.6 ± 8.0 7.6 ± 3.8 11.3 ± 9.4 0 64.8 ± 10.7 0.2 ± 0.3
D
d PDLLA 83.5 % porous 79.7 ± 6.4 8.8 ± 2.1 38.3 ± 21.2 0 35.0 ± 14.0 0
E
d BCP 29 % porous 27.4 ± 7.1 23.4 ± 1.8
e 40.4 ± 8.9
f 0 8.4 ± 7.0 0.5 ± 0.6
F
g 1000PEOT70PBT30 73.5 % porous no
CO2 plasma
45.0 ± 6.3 0 0 0 28.9 ± 23.8 55.1 ± 25.3
a Determined by histomorphometry
b Signiﬁcantly higher than scaffolds B,C,D and E
c Cartilage only observed in 1 out of 5 samples
d Average of 4 implants
e Signiﬁcantly higher than the other 5 scaffolds
f Signiﬁcantly higher than scaffolds A,B,C and F
g Average of 3 implants
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hydrophobic and rigid scaffolds like PDLLA or BCP, the
accessibility of the pore structure is more likely to be
preserved under the prevailing physiological conditions
than in hydrophilic 1000PEOT70PBT30 scaffolds. When
compared to 1000PEOT70PBT30 scaffolds, the PDLLA
and BCP scaffolds seem more suited for application in
bone tissue engineering. Further improvements, such as
adjustment of the PEOT/PBT composition in the poly-
mer used for the scaffolds, are necessary to increase the
amount of bone and bone marrow formed in the
scaffolds.
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cartilage has been formed upon subcutaneous implantation. The
few interconnections to other pores are indicated with arrows
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